CytomX Therapeutics
Stock Forecast, Prediction & Price Target
CytomX Therapeutics (CTMX) stock Price Target by analysts
$3.47
Potential upside: 73.24%
CytomX Therapeutics price prediction
What is CytomX Therapeutics stock analysts` prediction?
CytomX Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for CytomX Therapeutics in the last 3 months, the avarage price target is $3.47, with a high forecast of $NaN. The average price target represents a 73.24% change from the last price of $2.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
CytomX Therapeutics stock Price Target by analysts
Full breakdown of analysts given CytomX Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 25% 1/4 | 10 months ago | $3.68 83.99% upside | $1.09 | StreetInsider | Previous targets (3) |
Joseph Catanzaro Piper Sandler | 0% 0/2 | 10 months ago | $3.25 62.49% upside | $1.09 | StreetInsider | Previous targets (1) |
Etzer Darout BMO Capital | 25% 1/4 | about 1 year ago | $3.56 77.99% upside | $1.18 | StreetInsider | Previous targets (3) |
Joseph Catanzaro Piper Sandler | 0% 0/2 | over 1 year ago | $3.5 74.99% upside | $1.75 | TheFly | Previous targets (1) |
Etzer Darout BMO Capital | 25% 1/4 | over 1 year ago | $3.59 79.49% upside | $4.19 | StreetInsider | Previous targets (3) |
Robert Driscoll Wedbush | 0% 0/1 | over 1 year ago | $8 299.98% upside | $2.4 | StreetInsider | Previous targets (0) |
Roger Song Jefferies | 50% 1/2 | over 1 year ago | $8 299.98% upside | $4.46 | TheFly | Previous targets (1) |
Roger Song Jefferies | 50% 1/2 | over 1 year ago | $2.5 24.99% upside | $2.15 | StreetInsider | Previous targets (1) |
Etzer Darout BMO Capital | 25% 1/4 | over 1 year ago | $3.25 62.49% upside | $2.15 | StreetInsider | Previous targets (3) |
Unknown BMO Capital | N/A | over 2 years ago | $3.2 59.99% upside | $1.79 | Benzinga | N/A |
Unknown BMO Capital | N/A | almost 3 years ago | $2.6 29.99% upside | $1.29 | Benzinga | N/A |
CytomX Therapeutics Financial Estimates
CytomX Therapeutics Revenue Estimates
CytomX Therapeutics EBITDA Estimates
CytomX Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $69.57M N/A | $53.16M -23.58% | $101.21M 90.38% | Avg: $76.05M Low: $45.23M High: $91.79M avg. -24.85% | Avg: $43.4M Low: $28.59M High: $59.46M avg. -42.93% | Avg: $25M Low: $16.46M High: $34.25M avg. -42.39% | Avg: $95.60M Low: $62.98M High: $130.99M avg. 282.43% |
Net Income
% change YoY
| $-80.64M N/A | $-97.29M -20.64% | $-569K 99.41% | Avg: $-49.97M Low: $-45.24M High: $-20.66M avg. -8682.81% | Avg: $-85.59M Low: $-84.14M High: $-44.28M avg. -71.27% | Avg: $-73.43M Low: $-108.77M High: $-40.86M avg. 14.20% | Avg: $-38.01M Low: $-56.29M High: $-21.15M avg. 48.24% |
EBITDA
% change YoY
| $-83.78M N/A | $-101.33M -20.95% | $-4.30M 95.74% | Avg: $-53.26M Low: $-64.27M High: $-31.67M avg. -1136.03% | Avg: $-30.39M Low: $-41.63M High: $-20.02M avg. 42.93% | Avg: $-17.50M Low: $-23.98M High: $-11.53M avg. 42.39% | Avg: $-66.94M Low: $-91.72M High: $-44.10M avg. -282.43% |
EPS
% change YoY
| -$1.26 N/A | -$1.48 -17.46% | -$0.01 99.47% | Avg: -$0.47 Low: -$0.61 High: -$0.28 avg. -6037.79% | Avg: -$0.81 Low: -$1.14 High: -$0.6 avg. -72.09% | Avg: -$1 Low: -$1.47 High: -$0.55 avg. -22.33% | Avg: -$0.52 Low: -$0.76 High: -$0.29 avg. 48.24% |
Operating Expenses
% change YoY
| $153.35M N/A | $154.49M 0.74% | $107.69M -30.29% | Avg: $40.50M Low: $24.08M High: $48.88M avg. -62.39% | Avg: $23.11M Low: $15.22M High: $31.66M avg. -42.93% | Avg: $13.31M Low: $8.77M High: $18.23M avg. -42.39% | Avg: $50.91M Low: $33.54M High: $69.75M avg. 282.43% |
FAQ
What is CytomX Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -2172.91% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -45.24M, average is -49.97M and high is -20.66M.
What is CytomX Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 43.06% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $45.23M, average is $76.05M and high is $91.79M.
What is CytomX Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -1520.99% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.61, average is -$0.47 and high is $-0.28.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering CytomX Therapeutics stock. The most successful analyst is Etzer Darout whose win rate is 25%. He has correctly predicted 1/4 price targets.